140 related articles for article (PubMed ID: 21755401)
21. Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate.
Kendler DL; McClung MR; Freemantle N; Lillestol M; Moffett AH; Borenstein J; Satram-Hoang S; Yang YC; Kaur P; Macarios D; Siddhanti S;
Osteoporos Int; 2011 Jun; 22(6):1725-35. PubMed ID: 20827547
[TBL] [Abstract][Full Text] [Related]
22. Effect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis: a randomized placebo-controlled double-blind study.
Matsumoto T; Hagino H; Shiraki M; Fukunaga M; Nakano T; Takaoka K; Morii H; Ohashi Y; Nakamura T
Osteoporos Int; 2009 Aug; 20(8):1429-37. PubMed ID: 19101754
[TBL] [Abstract][Full Text] [Related]
23. Bisphosphonate prescribing, persistence and cumulative exposure in Ontario, Canada.
Burden AM; Paterson JM; Solomon DH; Mamdani M; Juurlink DN; Cadarette SM
Osteoporos Int; 2012 Mar; 23(3):1075-82. PubMed ID: 21604008
[TBL] [Abstract][Full Text] [Related]
24. Clinical evaluation of novel bisphosphonate dosing regimens in osteoporosis: the role of comparative studies and implications for future studies.
Cosman F; Borges JL; Curiel MD
Clin Ther; 2007 Jun; 29(6):1116-27. PubMed ID: 17692726
[TBL] [Abstract][Full Text] [Related]
25. Adherence and profile of non-persistence in patients treated for osteoporosis--a large-scale, long-term retrospective study in The Netherlands.
Netelenbos JC; Geusens PP; Ypma G; Buijs SJ
Osteoporos Int; 2011 May; 22(5):1537-46. PubMed ID: 20838773
[TBL] [Abstract][Full Text] [Related]
26. Differences in persistence among different weekly oral bisphosphonate medications.
Sheehy O; Kindundu CM; Barbeau M; LeLorier J
Osteoporos Int; 2009 Aug; 20(8):1369-76. PubMed ID: 19020921
[TBL] [Abstract][Full Text] [Related]
27. Long-term persistence and switching patterns among women using osteoporosis therapies: 24- and 36-month results from POSSIBLE US™.
Wade SW; Satram-Hoang S; Stolshek BS
Osteoporos Int; 2014 Sep; 25(9):2279-90. PubMed ID: 24942502
[TBL] [Abstract][Full Text] [Related]
28. How the knowledge of fracture risk might influence adherence to oral therapy of osteoporosis in Italy: the ADEOST study.
Gonnelli S; Caffarelli C; Rossi S; Di Munno O; Malavolta N; Isaia G; Muratore M; D'Avola G; Gatto S; Minisola G; Nuti R
Aging Clin Exp Res; 2016 Jun; 28(3):459-68. PubMed ID: 26873817
[TBL] [Abstract][Full Text] [Related]
29. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis.
Penning-van Beest FJ; Goettsch WG; Erkens JA; Herings RM
Clin Ther; 2006 Feb; 28(2):236-42. PubMed ID: 16678644
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.
Emkey R; Delmas PD; Bolognese M; Borges JL; Cosman F; Ragi-Eis S; Recknor C; Zerbini CA; Neate C; Sedarati F; Epstein S
Clin Ther; 2009 Apr; 31(4):751-61. PubMed ID: 19446148
[TBL] [Abstract][Full Text] [Related]
31. BONE TURNOVER IN OSTEOPOROTIC WOMEN DURING LONG-TERM ORAL BISPHOSPHONATES TREATMENT: IMPLICATIONS FOR TREATMENT FAILURE AND "DRUG HOLIDAY" IN THE REAL WORLD.
Liel Y; Plakht Y; Tailakh MA
Endocr Pract; 2017 Jul; 23(7):787-793. PubMed ID: 28448762
[TBL] [Abstract][Full Text] [Related]
32. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial.
Leder BZ; Tsai JN; Uihlein AV; Wallace PM; Lee H; Neer RM; Burnett-Bowie SA
Lancet; 2015 Sep; 386(9999):1147-55. PubMed ID: 26144908
[TBL] [Abstract][Full Text] [Related]
33. Relationship between compliance and persistence with osteoporosis medications and fracture risk in primary health care in France: a retrospective case-control analysis.
Cotté FE; Mercier F; De Pouvourville G
Clin Ther; 2008 Dec; 30(12):2410-22. PubMed ID: 19167600
[TBL] [Abstract][Full Text] [Related]
34. Persistence at 24 months with denosumab among postmenopausal women with osteoporosis: results of a prospective cohort study.
Silverman SL; Siris E; Belazi D; Recknor C; Papaioannou A; Brown JP; Gold DT; Lewiecki EM; Quinn G; Balasubramanian A; Yue S; Stolshek B; Kendler DL
Arch Osteoporos; 2018 Aug; 13(1):85. PubMed ID: 30088189
[TBL] [Abstract][Full Text] [Related]
35. Two-year persistence with teriparatide improved significantly after introduction of an educational and motivational support program.
van Maren MA; Wyers CE; Driessen JHM; Visser JV; de Vries F; van de Wijdeven K; Gevers S; Lems WF; Emmelot-Vonk MH; van den Bergh JPW
Osteoporos Int; 2019 Sep; 30(9):1837-1844. PubMed ID: 31321446
[TBL] [Abstract][Full Text] [Related]
36. International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates.
Diez-Perez A; Naylor KE; Abrahamsen B; Agnusdei D; Brandi ML; Cooper C; Dennison E; Eriksen EF; Gold DT; Guañabens N; Hadji P; Hiligsmann M; Horne R; Josse R; Kanis JA; Obermayer-Pietsch B; Prieto-Alhambra D; Reginster JY; Rizzoli R; Silverman S; Zillikens MC; Eastell R;
Osteoporos Int; 2017 Mar; 28(3):767-774. PubMed ID: 28093634
[TBL] [Abstract][Full Text] [Related]
37. Factors associated with high 24-month persistence with denosumab: results of a real-world, non-interventional study of women with postmenopausal osteoporosis in Germany, Austria, Greece, and Belgium.
Fahrleitner-Pammer A; Papaioannou N; Gielen E; Feudjo Tepie M; Toffis C; Frieling I; Geusens P; Makras P; Boschitsch E; Callens J; Anastasilakis AD; Niedhart C; Resch H; Kalouche-Khalil L; Hadji P
Arch Osteoporos; 2017 Dec; 12(1):58. PubMed ID: 28643265
[TBL] [Abstract][Full Text] [Related]
38. A systematic review of persistence and compliance with bisphosphonates for osteoporosis.
Cramer JA; Gold DT; Silverman SL; Lewiecki EM
Osteoporos Int; 2007 Aug; 18(8):1023-31. PubMed ID: 17308956
[TBL] [Abstract][Full Text] [Related]
39. One and two-year persistence with different anti-osteoporosis medications: a retrospective cohort study.
Reyes C; Tebe C; Martinez-Laguna D; Ali MS; Soria-Castro A; Carbonell C; Prieto-Alhambra D
Osteoporos Int; 2017 Oct; 28(10):2997-3004. PubMed ID: 28714038
[TBL] [Abstract][Full Text] [Related]
40. Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women.
Rabenda V; Mertens R; Fabri V; Vanoverloop J; Sumkay F; Vannecke C; Deswaef A; Verpooten GA; Reginster JY
Osteoporos Int; 2008 Jun; 19(6):811-8. PubMed ID: 17999022
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]